Core Viewpoint - MicroPort Cardiac Rhythm Management-B (02160) has announced that its next-generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN is set to enter the NMPA's special review process, potentially becoming the first domestically approved MRI-safe ICD with independent intellectual property rights in China [1][2] Group 1: Product Development - TILEN/EYLEN is a core product of a national key research and development project initiated by the Ministry of Science and Technology, aimed at filling a technological gap in the domestic market [1] - The ICD features automatic MRI functionality, significantly reducing patient discomfort caused by asynchronous modes and simplifying the MRI scanning process [1] - It includes remote follow-up capabilities based on low-power Bluetooth technology, enhancing patient compliance through a complete solution supported by domestic data centers [1] Group 2: Market Impact - Sudden Cardiac Death (SCD) is a leading cause of death globally, and ICDs have been proven to be the most effective measure for preventing SCD by restoring normal heart rhythm during life-threatening arrhythmias [2] - The company's PLATINIUM™ series ICD products received NMPA approval in September 2024, marking the first domestically approved ICD and providing more options for SCD prevention and treatment for Chinese patients [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]